PCSK9 inhibitors lower circulating LDL-C levels by blocking the degradation of LDL-R by PCSK9.

Selecting TYK2 inhibitors can reduce the inhibition of other immune-related pathways in the body, reduce the risk of infection, and be safer in clinical practice.

SGLT2 inhibitors not only can effectively lower blood sugar, but also bring significant cardiorenal protective effects.

Thrombin inhibitors are drugs that specifically target and inhibit thrombin, a key enzyme in blood clotting.

The development of STAT3 inhibitors will be increasingly valued in the future, and targeting the STAT3 signaling pathway has become a promising strategy for the treatment of various cancers.

ROCK2 inhibitors are drugs targeting the ROCK2 enzyme, crucial in various cellular processes.

The search for more sensitive and safer specific RET inhibitors to provide precision treatment and personalized treatment for cancer patients will be the main research direction in the future.

Protease inhibitors are drugs that inhibit proteases, enzymes crucial in various biological processes.

RIPK1 inhibitors are drugs that target the enzyme RIPK1, crucial in cell death and inflammation regulation.

Protein kinase inhibitors are drugs that target protein kinases, crucial in cell signaling and regulation. The future sees potential applications in treating various diseases, particularly cancer.

Due to the important role that arginine methylation plays in the development of cancer, PRMT5 has become a potential target for cancer treatment.

Ras inhibitors are drugs that target Ras proteins, crucial in cell signaling pathways. The future sees potential applications in treating various cancers.